Antiendothelial cell antibodies: Useful markers of systemic sclerosis

American Journal of Medicine

Volumn 102, Issue 2, 1997, Pages 178-185

  Salojin, Konstantin V ^a   Le Tonquèze, Michelle ^a   Saraux, Alain ^a   Nassonov, Evgeni L ^b   Dueymes, Maryvonne ^a   Piette, Jean Charles ^c   Youinou, Pierre Y ^a,d  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CELL ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE; THROMBOMODULIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; RAYNAUD DISEASE; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; THROMBOMODULIN; VON WILLEBRAND FACTOR;

EID: 0030905052     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00404-4     Document Type: Article

References (40)

1. Medsger TA Jr, Steen VD. Classification prognosis. In: Clements PJ, Furst DE, eds. Systemic Sclerosis. Baltimore: Williams & Wilkins; 1996:51-64.
2. Winterbauer RH. Multiple telangiectasia, Raynaud's phenomenon, sclerodactyly and subcutaneous calcinosis: a syndrome mimicking hereditary hemorrhagic telangiectasia. Bull Johns Hopkins Hosp. 1964;114:361-383.
3. LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10:485-488.
4. Moroi Y, Peebles C, Fritzler MJ, et al. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA. 1980;77:1627-1631.
5. Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem. 1979;254:10514-10522.
6. Pearson JD. Markers of endothelial perturbation and damage. Br J Rheumatol. 1993;3:651-652.
7. Matucci-Cerinic M, Pignone A, Lotti T, et al. Reduced angiotensin enzyme plasma activity in scleroderma. A marker of endothelial injury? J Rheumatol. 1990;17:328-330.
8. Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med. 1981;94:482-484.
9. Soma Y, Takehara K, Sato S, Ishibashi Y. Increase in plasma thrombomodulin in patients with systemic sclerosis. J Rheumatol. 1993;20:1444-1445.
10. Kahaleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. J Exp Med. 1979;149:1326-1335.
11. Lindqvist KJ, Osterland CK. Human antibodies to vascular endothelium. Clin Exp Immunol. 1971;9:753-760.
12. Tan EM, Pearson CM. Rheumatic disease sera reactive with capillaries in the mouse kidney. Arthritis Rheum. 1972;15:23-28.
13. Cines DB, Lyss AP, Reeber M, et al. Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. J Clin Invest. 1984;73:611-625.
14. Hashemi S, Smith CD, Izaguirre CA. Anti-endothelial cell antibodies. Detection and characterization using a cellular enzyme-linked immunosorbent assay. J Lab Clin Med. 1987;109:434-440.
15. Youinou P, Meroni PL, Khamashta MA, Shoenfeld Y. A need for standardization of the anti-endothelial cell antibody test. Immunol Today. 1995;16:363-364.
16. Edgell CJS, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA. 1983;80:3734-3737.
17. Meroni PL. What is going to happen tomorrow in the field of anti-endothelial cell autoantibodies related to vasculitis? Ann Med Int. 1991;94:467-468.
18. Masi AT, Rodnan GP, Medsger TA Jr, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;25:581-590.
19. Clements PG, Lachenbruch PA, Ng SC, et al. Skin score: a semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum. 1990;33:1256-1264.
20. Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988;34:196-203.
21. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993;36:340-347.
22. Brennan P, Silman A, Black C, et al. Validity and reliability of the methods used in the diagnosis of Raynaud's phenomenon. Br J Rheumatol. 1993;92:357-361.
23. Sarkozy J, Bookman AAM, Lee P, et al. Significance of the anticentromere antibody in idiopathic Raynaud's syndrome. Am J Med. 1987;83:393-398.
24. Blann AD, Illingworth K, Jayson MIV. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol. 1993;20:1325-1330.
25. Salojin KV, Le Tonquèze M, Nassonov EL, et al. Anti-endothelial cell antibodies in patients with various forms of vasculitis. Clin Exp Rheumatol. 1996;14:163-169.
26. Rosenbaum J, Pottinger BE, Woo P, et al. Measurement and characterization of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol. 1988;72:450-456.
27. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half of the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
28. Herrick AL, Illingworth K, Blann A, et al. Von Willebrand factor, thrombomodulin, thromboxane, β-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis. 1996;55:122-127.
29. Soma Y, Takehara K, Sato S, Ishibashi Y. Increase in plasma thrombomodulin in patients with systemic sclerosis. J Rheumatol. 1993;20:1444-1445.
30. Kallenberg CG, Wouda AA. Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon. Am J Med. 1980;69:675-680.
31. Tuffaneli DL, McKeon F, Kleinsmith DM, et al. Anticentromere and anticentriole antibodies in the scleroderma spectrum. Arch Dermatol. 1983;119:560-566.
32. Meroni PL, Youinou P. Anti-endothelial cell antibodies. In: Shoenfeld Y, Peter JB, eds. Textbook of Autoantibodies. 1996;618-623.
33. McNeilage LJ, Youngchaiyud LJ, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum. 1989;32:54-60.
34. Reveille JD, Durban E, Goldstein R, et al. Racial differences in the frequencies of scleroderma related autoantibodies. Arthritis Rheum. 1992;35:216-218.
35. Genth E, Mierau R, Genetzky P, et al. Immunogenetic associations of scleroderma related antinuclear antibodies. Arthritis Rheum. 1990;33:657-665.
36. Le Tonquèze M, Jamin C, Böhme M, et al. Establishment and characterization of permanent human endothelial cell clones. Lupus. 1996;5:103-112.
37. Del Papa N, Guidali L, Sironi M, et al. Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. Arthritis Rheum. 1996;39:758-766.
38. Carson CW, Beall LD, Hunder GG, et al. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol. 1993;20:809-814.
39. Holt CM, Lindsey N, Moult J, et al. Antibody-dependent cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. Clin Exp Immunol. 1989;78:359-365.
40. Del Papa N, Meroni PL, Barcellini W, et al. Antibodies to endothelial cells in primary vasculitidis mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. Clin Immunol Immunopathol. 1992;63:267-274.